Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07157969 | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | recruiting | Phase 2 | 300 | Peking Union Medical College HospitalOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07241663 | Surgery for Locally Unresectable Pancreatic Cancer(ROBIN) | recruiting | — | 150 | Azienda Ospedaliera di PadovaOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06632717 | Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 24 | National Taiwan University HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07239245 | Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo(ATTACH) | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07243691 | Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma | recruiting | N/A | 33 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06544629 | Imjudo & Imfinzi PMS | recruiting | — | 246 | AstraZenecaINDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07235410 | Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE | recruiting | — | 300 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07237464 | To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants | recruiting | Phase 1 | 36 | Shenzhen Kexing Pharmaceutical Co., Ltd.NETWORK | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05751343 | Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial | recruiting | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04115254 | Stereotactic Magnetic Resonance Guided Radiation Therapy | recruiting | N/A | 397 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06600906 | Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer | recruiting | — | 70 | University of California, San FranciscoOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT06698250 | Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)(ZENOBIA) | recruiting | Phase 2 | 40 | Anwaar SaeedOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | recruiting | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT03484299 | Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma | recruiting | Phase 1 | 20 | University of LouisvilleOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT06984562 | Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer | recruiting | N/A | 16 | Fox Chase Cancer CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT02000089 | The Cancer of the Pancreas Screening-5 CAPS5)Study(CAPS5) | recruiting | Phase 3 | 9,000 | Johns Hopkins UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT03551951 | Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow | recruiting | — | 320 | University of Missouri-ColumbiaOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT06789757 | The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)((HCC)) | recruiting | Phase 2 | 19 | Inova Health Care ServicesOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05377034 | Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients(STRATUM) | recruiting | Phase 2 | 100 | National Cancer Centre, SingaporeOTHER | 4 | Oct 6, 2025 | clinicaltrials |
| NCT03492671 | Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer | recruiting | Phase 2 | 30 | Loma Linda UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07179692 | CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | recruiting | Phase 1 | 108 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04361708 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies(I-FLOAT) | recruiting | Phase 1 | 54 | University of ChicagoOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06182072 | ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 1 | 46 | ProDa BioTech, LLCINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06349317 | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT | recruiting | Phase 2 | 33 | Yongyi ZengOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06467799 | Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC | recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05116072 | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula(TPIAT-01) | recruiting | Phase 1 / Phase 2 | 36 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07192185 | Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05971108 | Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC(REVISE-HCC) | recruiting | N/A | 600 | Manchester University NHS Foundation TrustOTHER_GOV | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06644937 | Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence | recruiting | Phase 2 / Phase 3 | 30 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06658782 | Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer(AMULET) | recruiting | — | 300 | University of OxfordOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186010 | Immunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy | recruiting | — | 50 | Asan Medical CenterOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186621 | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | recruiting | Phase 3 | 286 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04525833 | Liver Disease and Other Systemic Diseases | recruiting | — | 15,000 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07155525 | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas(NBCA-MS) | recruiting | Phase 3 | 194 | Minia UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07178093 | Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization | recruiting | N/A | 60 | Taichung Tzu Chi HospitalOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07176962 | A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening | recruiting | — | 1,800 | Yingbin Liu, MD, PhD, FACSOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07170345 | Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion(HCC-MVI-CAD) | recruiting | — | 400 | Chinese Academy of SciencesOTHER_GOV | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06179602 | Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors(A-IMAGIO) | recruiting | — | 1,500 | Leiden University Medical CenterOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06831136 | Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma(PANCARDINAL-2) | recruiting | Phase 2 | 24 | The University of Texas Health Science Center, HoustonOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06999694 | Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC(Proton-STRIDE) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07148310 | Hepatocellular Carcinoma Identification Using Delta-HLD(HIDE) | recruiting | — | 200 | Epiliquid Holding, IncINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07154082 | Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 27 | Wei ZhangOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06902389 | A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 30 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06202131 | Use of Ctdna in Patients With Gastrointestinal Tract Tumors(ctdna-GI) | recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06541990 | Psychoeducational Intervention for Patients With Hepatocellular Carcinoma(HARMONY) | recruiting | N/A | 50 | Massachusetts General HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 1, 2025source: clinicaltrials